Smith Graham Investment Advisors Lp buys $9,765,266 stake in PharMerica Corporation (PMC)

PharMerica Corporation (PMC) : Smith Graham Investment Advisors Lp scooped up 10,510 additional shares in PharMerica Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 17, 2016. The investment management firm now holds a total of 360,209 shares of PharMerica Corporation which is valued at $9,765,266.PharMerica Corporation makes up approximately 1.26% of Smith Graham Investment Advisors Lp’s portfolio.

Other Hedge Funds, Including , Gemmer Asset Management reduced its stake in PMC by selling 34 shares or 27.64% in the most recent quarter. The Hedge Fund company now holds 89 shares of PMC which is valued at $2,413. Msi Financial Services Inc sold out all of its stake in PMC during the most recent quarter. The investment firm sold 6,515 shares of PMC which is valued $179,293.Creative Planning boosted its stake in PMC in the latest quarter, The investment management firm added 626 additional shares and now holds a total of 1,307 shares of PharMerica Corporation which is valued at $35,603.Legal General Group Plc boosted its stake in PMC in the latest quarter, The investment management firm added 24,456 additional shares and now holds a total of 30,189 shares of PharMerica Corporation which is valued at $822,348.Fisher Asset Management reduced its stake in PMC by selling 24,531 shares or 21.49% in the most recent quarter. The Hedge Fund company now holds 89,621 shares of PMC which is valued at $2,501,322.

PharMerica Corporation closed down -0.41 points or -1.49% at $27.11 with 1,83,588 shares getting traded on Friday. Post opening the session at $27.65, the shares hit an intraday low of $27.05 and an intraday high of $27.92 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, PharMerica Corporation reported $0.47 EPS for the quarter, based on the information available during the earnings call on Aug 9, 2016. Analyst had a consensus estimate of $0.47. The company had revenue of $519.60 million for the quarter, compared to analysts expectations of $508.31 million. The company’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.48 EPS.

PharMerica Corporation is an institutional pharmacy services company. The Company has three operating segments: institutional pharmacy specialty infusion services and specialty oncology pharmacy. The Company’s core business institutional pharmacy segment provides pharmacy products and services to residents and patients in skilled nursing facilities nursing centers assisted living facilities hospitals and other long-term alternative care settings. The Company’s specialty infusion services segment provides specialty infusion services focused on providing pharmaceutical products and clinical services to patients in client facilities hospice and outside of hospital or nursing home settings. The Company’s specialty oncology pharmacy segment provides dispensing of oncology drugs care management and other related services to patients oncology practices and hospitals.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

PharMerica Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on PharMerica Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.